Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023202 · ClinicalTrials.gov registry record
UWCCC Molecular Tumor Board Registry
A clinical trial of Hematologic Neoplasms and Solid Neoplasm, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT03023202 is a study of Hematologic Neoplasms and Solid Neoplasm that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 10,000 participants, above the 526-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (1801% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03023202, a study of Hematologic Neoplasms and Solid Neoplasm, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Conditions Studied
Interventions
- OTHER PMMTB (Precision Medicine Molecular Tumor Board)
Study Locations (1)
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03023202
The ClinicalTrials.gov registry entry for NCT03023202 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 526-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (1801% higher). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PMMTB (Precision Medicine Molecular Tumor Board) is the first listed.
NCT03023202 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03023202 about?
NCT03023202 is a clinical study titled "UWCCC Molecular Tumor Board Registry". This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
What is the current status of trial NCT03023202?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2016-03-30. Estimated completion is 2027-03.
What conditions does trial NCT03023202 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, Solid Neoplasm.
What interventions are being tested in trial NCT03023202?
The interventions under investigation include: PMMTB (Precision Medicine Molecular Tumor Board) (OTHER).
Who is sponsoring clinical trial NCT03023202?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03023202 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.